English  |  正體中文  |  简体中文  |  2854334  
???header.visitor??? :  53356824    ???header.onlineuser??? :  688
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

???jsp.browse.items-by-title.jump??? [ ???jsp.browse.general.jump2chinese??? ] [ ???jsp.browse.general.jump2numbers??? ] [ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ]
???jsp.browse.items-by-title.enter???   

Showing items 431031-431055 of 2348971  (93959 Page(s) Totally)
<< < 17237 17238 17239 17240 17241 17242 17243 17244 17245 17246 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-02-12T04:06:09Z First- and second-trimester down syndrome screening: Current strategies and clinical guidelines Cheng P.-J.;Hsieh T.-T;Chen C.-P;Hsiao C.-H;CHIEN-NAN LEE;Hsu J.-J;Shaw S.-W; Shaw S.-W; Hsu J.-J; CHIEN-NAN LEE; Hsiao C.-H; Chen C.-P; Hsieh T.-T; Cheng P.-J.
義守大學 2014-05 First- and Third-Person Perceptions: Using the Ostensible Audience as a Comparison Anchor in the Processes of Downward and Upward Social Comparisons Sue-Jen Lin
臺大學術典藏 2018-09-10T06:51:20Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu, J.-Y. and Yu, C.-J. and Yang, C.-H. and Wu, S.-G. and Chiu, Y.-H. and Gow, C.-H. and Chang, Y.-C. and Hsu, Y.-C. and Wei, P.-F. and Shih, J.-Y. and Yang, P.-C.; YEUN-CHUNG CHANG; Chong-Jen Yu; PAN-CHYR YANG; JIN-YUAN SHIH
臺大學術典藏 2020-05-26T09:27:21Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Yang P.-C.;Shih J.-Y;Wei P.-F;Hsu Y.-C;Chang Y.-C;Gow C.-H;Chiu Y.-H;Wu S.-G;Chih-Hsin Yang;Yu C.-J;Wu J.-Y; Wu J.-Y; Yu C.-J; CHIH-HSIN YANG; Wu S.-G; Chiu Y.-H; Gow C.-H; Chang Y.-C; Hsu Y.-C; Wei P.-F; Shih J.-Y; Yang P.-C.
臺大學術典藏 2020-08-12T08:25:31Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu J.-Y.; Yu C.-J.; Yang C.-H.; SHANG-GIN WU; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C.
臺大學術典藏 2020-08-13T06:34:00Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu J.-Y.; Yu C.-J.; Yang P.-C.; JIN-YUAN SHIH; Wei P.-F.; Hsu Y.-C.; Chang Y.-C.; Gow C.-H.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.
臺大學術典藏 2020-12-02T02:34:31Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Pan-Chyr Yang; Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; PAN-CHYR YANG
臺大學術典藏 2021-03-19T06:57:51Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; YEUN-CHUNG CHANG; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C.
臺大學術典藏 2022-06-27T07:07:54Z First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer Wu J.-Y.; CHONG-JEN YU; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C.
國立臺灣大學 2008-10 First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Wu, Jenn-Yu; Yu, Chong-Jen; Chih-HsinYang; Wu, Shang-Gin; Chiu, Yueh-Hsia; Gow, Chien-Hung; Chang, Yeun-Chung; Hsu, Ya-Chieh; Wei, Pin-Fei; Shih, Jin-Yuan; Yang, Pan-Chyr
慈濟大學 2012 First-attack pediatric hypertensive crisis presenting to the pediatric emergency department Yang, Wen-Chieh;Zhao, Lu-Lu;Chen, Chun-Yu;Wu, Yung-Kang;Chang, Yu-Jun;Wu, Han-Ping
淡江大學 2007-03 First-Best Tax Policy, Congestion, and Imperfect Competition Hung, Hsiao-wen
中原大學 2001 First-come-First-Served Polling Systems Kuo-Hwa Chang
國立交通大學 2019-04-03T06:40:15Z First-ever ischemic stroke in elderly patients: predictors of functional outcome following carotid artery stenting Lin, Chih-Ming; Chang, Yu-Jun; Liu, Chi-Kuang; Yu, Cheng-Sheng; Lu, Henry Horng-Shing
亞洲大學 2016-11 First-ever stroke following hip replacement surgeries: a large population-based survey. Wang, Chia-To;Wang, Chia-To;Chuang, Eric;Chuang, Eric;Yen, Der-Jen;Yen, Der-Jen;Chu, Tien-Yow;Chuang, Tien-Yow;Mu, Chih-Hsin;Muo, Chih-Hsin;高嘉鴻;Kao, Chia-Hung;*
淡江大學 2012-07-06 First-fit chromatic numbers of d-degenerate graphs Chang, Gerard Jennhwa;Hsu, Hsiang-Chun
國立臺灣大學 2012 First-generation college students' information seeking: Their personality traits and source use behavior in coursework-related context TIEN-I TSAI; Tsai, T.-I. and Kim, K.-S.
國立高雄師範大學 1998 First-grade children’s use of analogy in word reading C. C. Wang;J. S. Gaffney
國家衛生研究院 2021-08-12 First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients Huang, JF;Dai, CY;Huang, CF;Tsai, PC;Yeh, ML;Hsu, PY;Huang, SF;Bair, MJ;Hou, NJ;Huang, CI;Liang, PC;Lin, YH;Wang, CW;Hsieh, MY;Chen, SC;Lin, ZY;Yu, ML;Chuang, WL
國家衛生研究院 2024-01-29 First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo Sharma, S;Wang, SA;Yang, WB;Lin, HY;Lai, MJ;Chen, HC;Kao, TY;Hsu, FL;Nepali, K;Hsu, TI;Liou, JP
臺大學術典藏 2021-07-21T23:21:30Z First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma Italiano, Antoine; Cassier, Philippe A.; Chia-Chi Lin; Alanko, Tuomo; Peltola, Katriina J.; Gazzah, Anas; Shiah, Her Shyong; Calvo, Emiliano; Cervantes, Andrés; Roda, Desamparados; Tosi, Diego; Gao, Bo; Millward, Michael; Warburton, Lydia; Tanner, Minna; Englert, Stefan; Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E.; Vosganian, Gregory; Moreno, Victor
臺大學術典藏 2022-09-15T01:08:44Z First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V.
國立臺灣大學 2015 First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan; 楊志新
臺大學術典藏 2021-08-11T03:46:35Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
國立成功大學 2019 First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K.

Showing items 431031-431055 of 2348971  (93959 Page(s) Totally)
<< < 17237 17238 17239 17240 17241 17242 17243 17244 17245 17246 > >>
View [10|25|50] records per page